Get started
Author

Jakub Kucharz

Observed names: J. Kucharz, JAKUB KUCHARZ, Jakub KUCHARZ, Kucharz, Jakub, Kucharz, Jakub; Klinika Nowotworów Układu Moczowego, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
ORCID: 0000-0001-5388-8910
Observed ORCID: 0000-0001-5388-8910
OpenAlex ID: A5026242279
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
2023 · Matteo Santoni, Alessandro Rizzo, et al. · Cancer Immunology Immunotherapy · 151
PDF
Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients
2018 · Agnieszka Żyłka, Paulina Dumnicka, et al. · Mediators of Inflammation · 102
PDF
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
2023 · Matteo Santoni, Sebastiano Buti, et al. · European Urology Oncology · 92
Factors Affecting Sexual Function and Body Image of Early-Stage Breast Cancer Survivors in Poland: A Short-Term Observation
2018 · Robert Kowalczyk, Krzysztof Nowosielski, et al. · Clinical Breast Cancer · 85
Contemporary treatment of metastatic renal cell carcinoma
2018 · Pawel Wiechno, Jakub Kucharz, et al. · Medical Oncology · 60
High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience
2017 · Iwona Filipczak-Bryniarska, Roger M. Krzyzewski, et al. · Medical Oncology · 57
PDF
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
2023 · Matteo Santoni, Francesco Massari, et al. · Targeted Oncology · 47
PDF
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
2017 · Anna Buda-Nowak, Jakub Kucharz, et al. · Medical Oncology · 47
PDF
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
2023 · Matteo Santoni, Francesco Massari, et al. · Clinical Genitourinary Cancer · 33
PDF
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
2023 · Ondřej Fiala, Sebastiano Buti, et al. · Cancer Immunology Immunotherapy · 31
PDF
Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor
2017 · Paweł J. Wiechno, Maria Kowalska, et al. · Medical Oncology · 26
PDF
Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer
2020 · Łukasz Kuncman, Konrad Stawiski, et al. · Strahlentherapie und Onkologie · 24
PDF
Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report
2016 · JAKUB KUCHARZ, ANNA MICHALOWSKA-KACZMARCZYK, et al. · Oncology Letters · 23
PDF
Lack of antiretroviral therapy is associated with higher risk of neurosyphilis among HIV-infected patients who remain serofast after therapy for early syphilis
2018 · Maciej Pastuszczak, Marek Sitko, et al. · Medicine · 20
Chemotherapy-Induced Takotsubo Syndrome
2018 · Monika Budnik, Jakub Kucharz, et al. · Advances in experimental medicine and biology · 20
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
2024 · Ondřej Fiala, Francesco Massari, et al. · Targeted Oncology · 19
PDF
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023 · Camillo PORTA, Aristotelis BAMIAS, et al. · Minerva Urology and Nephrology · 19
PDF
Folia Medica Cracoviensia
2020 · Budnik, Monika, Białek, Sławomir, et al. · PubMed · 19
Co-occurring Adverse Events Enable Early Prediction of Progression-free Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib: A Hypothesis-generating Study
2015 · Jakub Kucharz, Paulina Dumnicka, et al. · Tumori Journal · 19
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
2025 · Camillo Porta, Francesco Massari, et al. · Cancer Immunology Immunotherapy · 18
PDF
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
2024 · Francesco Massari, Matteo Santoni, et al. · Cancer Immunology Immunotherapy · 18
PDF
Serum Uromodulin Levels in Prediction of Acute Kidney Injury in the Early Phase of Acute Pancreatitis
2017 · Beata Kuśnierz-Cabala, Agnieszka Gala-Błądzińska, et al. · Molecules · 18
PDF
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
2023 · Matteo Santoni, Zin W. Myint, et al. · Cancer Immunology Immunotherapy · 17
PDF
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
2016 · Jakub Kucharz, Agnieszka Giza, et al. · Medical Oncology · 17
PDF
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
2024 · Francesco Massari, Veronica Mollica, et al. · European Urology Oncology · 16
Works count: 103
Citation count: 1,314
H-index: 19
I10-index: 37
Year
Topic
Type